In patients in whom a cancer vaccine alone is ineffective, the induction of PD-L1 expression is thought to be the cause of the reduced efficacy, so the combination of a cancer vaccine with a PD-(L)1 antibody is expected to be effective. Here, CD274 is linked to cancer.